Lyell Immunopharma Stock Price Down 7.5 percent - MarketBeat
LYEL Stock | USD 0.65 0.02 2.99% |
About 60% of Lyell Immunopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Lyell Immunopharma suggests that many traders are alarmed. Lyell Immunopharma's investing sentiment shows overall attitude of investors towards Lyell Immunopharma.
Lyell |
Lyell Immunopharma Stock Price Down 7.5 MarketBeat
Read at news.google.com
Lyell Immunopharma Fundamental Analysis
We analyze Lyell Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyell Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyell Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Lyell Immunopharma is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Lyell Immunopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lyell Immunopharma stock to make a market-neutral strategy. Peer analysis of Lyell Immunopharma could also be used in its relative valuation, which is a method of valuing Lyell Immunopharma by comparing valuation metrics with similar companies.
Peers
Lyell Immunopharma Related Equities
EWTX | Edgewise Therapeutics | 18.36 | ||||
STTK | Shattuck Labs | 5.50 | ||||
MRUS | Merus BV | 4.91 | ||||
NUVB | Nuvation Bio | 3.07 | ||||
MLYS | Mineralys Therapeutics, | 1.56 | ||||
CRNX | Crinetics Pharmaceuticals | 1.35 | ||||
RVMD | Revolution Medicines | 1.01 | ||||
CGEM | Cullinan Oncology | 0.43 | ||||
INBX | Inhibrx | 0.07 | ||||
GLUE | Monte Rosa | 0.13 | ||||
NKTX | Nkarta | 1.28 | ||||
KRON | Kronos Bio | 2.04 | ||||
SANA | Sana Biotechnology | 2.55 | ||||
IPSC | Century Therapeutics | 4.10 | ||||
CCCC | C4 Therapeutics | 6.03 | ||||
GBIO | Generation Bio | 6.03 |
Check out Lyell Immunopharma Hype Analysis, Lyell Immunopharma Correlation and Lyell Immunopharma Performance. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.